In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 3, 2007, Pages 277-281

  Shuford, Jennifer A ^a   Piper, Kerryl E ^a   Steckelberg, James M ^a   Patel, Robin ^a  

^a Mayo Clinic   (United States)

Author keywords

Biofilm; Candida albicans; Caspofungin; Combination therapy; Voriconazole

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; DEOXYCHOLIC ACID; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONTROLLED STUDY; DRY WEIGHT; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL; SESSILE SPECIES;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 33847255390     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.09.004     Document Type: Article

References (22)

1. Bachmann S.P., VandeWalle K., Ramage G., Patterson T.F., Wickes B.L., Graybill J.R., and Lopez-Ribot J.L. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46 (2002) 3591-3596
2. Bachmann S.P., Ramage G., VandeWalle K., Patterson T.F., Wickes B.L., and Lopez-Ribot J.L. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob. Agents Chemother. 47 (2003) 3657-3659
3. Baillie G.S., and Douglas L.J. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol. 310 (1999) 644-656
4. Chandra J., Kuhn D.M., Mukherjee P.K., Hoyer L.L., McCormick T., and Ghannoum M.A. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183 (2001) 5385-5394
5. Chandra J., Mukherjee P.K., Leidich S.D., Faddoul F.F., Hoyer L.L., Douglas L.J., and Ghannoum M.A. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J. Dent. Res. 80 (2001) 903-908
6. Clinical and Laboratory Standards Institute. Method for broth dilution testing of yeasts. 2nd ed. Approved; standard M27-A2 (2002), CLSI, Wayne (PA)
7. Cocuaud C., Rodier M.H., Daniault G., and Imbert C. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J. Antimicrob. Chemother. 56 (2005) 507-512
8. Hawser S.P., and Douglas L.J. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect. Immun. 62 (1994) 915-921
9. Hawser S.P., and Douglas L.J. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39 (1995) 2128-2131
10. Hawser S.P., Norris H., Jessup C.J., and Ghannoum M.A. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J. Clin. Microbiol. 36 (1998) 1450-1452
11. Kuhn D.M., Chandra J., Mukherjee P.K., and Ghannoum M.A. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect. Immun. 70 (2002) 878-888
12. Kuhn D.M., George T., Chandra J., Mukherjee P.K., and Ghannoum M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46 (2002) 1773-1780
13. Kumar C.P., and Menon T. Biofilm production by clinical isolates of Candida species. Med. Mycol. 44 (2006) 99-101
14. Mermel L.A., Farr B.M., Sherertz R.J., Raad I.I., O'Grady N., Harris J.S., and Craven D.E. Guidelines for the management of intravascular catheter-related infections. Clin. Infect. Dis. 32 (2001) 1249-1272
15. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., and Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47 (2003) 3149-3154
16. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., Chaturvedi V., Ghannoum M.A., Odds F.C., Rinaldi M.G., Sheehan D.J., Troke P., Walsh T.J., and Warnock D.W. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44 (2006) 819-826
17. Ramage G., Vande Walle K., Wickes B.L., and Lopez-Ribot J.L. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45 (2001) 2475-2479
18. Ramage G., VandeWalle K., Bachmann S.P., Wickes B.L., and Lopez-Ribot J.L. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46 (2002) 3634-3636
19. Shuford J., Rouse M., Piper K., Steckelberg J., and Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J. Infect. Dis. 194 (2006) 710-713
20. Stevens D.A., Espiritu M., and Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48 (2004) 3407-3411
21. Stone J.A., Holland S.D., Wickersham P.J., Sterrett A., Schwartz M., Bonfiglio C., Hesney M., Winchell G.A., Deutsch P.J., Greenberg H., Hunt T.L., and Waldman S.A. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46 (2002) 739-745
22. Tortorano A.M., Prigitano A., Biraghi E., Viviani M.A., and Group F.-E.C.S. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J. Antimicrob. Chemother. 56 (2005) 777-779